355 ALHAMBRA CIRCLE, CORAL GABLES, FL
Amended material disclosure
Other Events
Other Events, Press Release
Investor Presentation
Reports Third Quarter 2025 Financial Results and Provides Business Update
Announces $200 Million Share Repurchase Program
Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence